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Abstract
Aims There is little evidence-based therapy existing for acute heart failure (AHF), hospitalizations are lengthy and expensive,
and optimal monitoring of AHF patients during in-hospital treatment is poorly defined. We evaluated a rapid cardiothoracic
ultrasound (CaTUS) protocol, combining focused echocardiographic evaluation of cardiac filling pressures, that is, medial
E/e0 and inferior vena cava index, with lung ultrasound (LUS) for guiding treatment in hospitalized AHF patients.
Methods and results We enrolled 20 consecutive patients hospitalized for AHF, whose in-hospital treatment was guided
using the CaTUS protocol according to a pre-specified treatment protocol targeting resolution of pulmonary congestion on
LUS and lowering cardiac filling pressures. Treatment results of these 20 patients were compared with those of a standard care
sample of 100 patients, enrolled previously for follow-up purposes. The standard care sample had CaTUS performed daily for
follow-up and received standard in-hospital treatment without ultrasound guidance. All CaTUS exams were performed by a
single experienced sonographer. The CaTUS-guided therapy resulted in significantly larger decongestion as defined by
reduction in symptoms, cardiac filling pressures, natriuretic peptides, cumulative fluid loss, and resolution of pulmonary
congestion (P < 0.05 for all) despite a shorter mean length of hospitalization. Congestion parameters were significantly lower
also at discharge (P < 0.05 for all), without any significant difference in these parameters on admission. The treatment arm
displayed better survival regarding the combined endpoint of 6 month all-cause death or AHF re-hospitalization (log rank
P = 0.017). No significant difference in adverse events occurred between the groups.
Conclusions The CaTUS-guided therapy for AHF resulted in greater decongestion during shorter hospitalization without
increased adverse events in this small pilot study and might be associated with a better post-discharge prognosis.
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Introduction
The global prevalence of heart failure (HF) is growing increas-
ingly.1 Most of the costs associated with HF are related to
hospitalizations due to decompensated HF, also known as
acute HF (AHF), which has become one of the leading causes
for hospitalization globally.2,3 There is to date virtually no
evidence-based therapy existing for AHF, hospitalizations
are lengthy and expensive,2,3 and post-discharge prognosis
often remains poor,4,5 underlining the need for better
evidence-based therapy. How to optimally monitor deconges-
tive treatment in AHF, however, is vaguely defined in the
guidelines,6,7 which might partly explain the lack of
effective therapies.8–10
Acute heart failure patients represent a heterogeneous
group of patients with varying underlying cardiac and cardio-
vascular disease and haemodynamic phenotypes.2,3,8 Accord-
ing to some authorities, tailored therapy based on individual
patient characteristics could also be a way to achieve more
effective therapy in AHF.8–10
Current HF guidelines recommend daily evaluation of signs
and symptoms of congestion, fluid balance, vital signs, body
weight, and renal function in hospitalized AHF patients, and
adjustment of decongestive therapy accordingly, while
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natriuretic peptides are considered non-useful for routine
treatment guidance.6,7 Of the adjunct monitoring tools,
echocardiography (echo) and lung ultrasound (LUS) allow
real-time evaluation of cardiac filling pressures and pulmo-
nary congestion, and these two modalities can be performed
sequentially using the same machinery and probe.11–14 Fur-
thermore, echo can specify the underlying cardiac disease
in AHF.4,5 Echo and LUS might thus be useful for determining
haemodynamic and baseline disease phenotype in AHF, as
well as for monitoring and individually guiding treatment.
There are, however, no studies to date on daily monitoring
of AHF therapy using a combined echo and LUS protocol, to
our best knowledge.
We hypothesized that individual, aggressive decongestive
AHF therapy guided by a cardiothoracic ultrasound (CaTUS)
protocol, combining echo-derived cardiac filling pressures
and LUS, could resolve congestion more effectively during a
shorter hospitalization period and perhaps be related with
an improved prognosis. The primary aim in this small non-
randomized single-centre pilot study, hence, was to evaluate
the efficacy of daily CaTUS-guided AHF therapy in terms of
improvement in various congestion parameters, that is,
ultrasound-derived cardiac filling pressures and pulmonary
congestion, natriuretic peptides, symptoms, and fluid loss.
The secondary aim in this study was to assess the safety
and feasibility of ultrasound-guided therapy, as well as its
impact on post-discharge prognosis.
Methods
We enrolled a population of 20 consecutive dyspnoeic
patients entering our tertiary hospital emergency depart-
ment (ED) and meeting the inclusion criteria between May
and June 2015. These 20 patients received CaTUS-guided
treatment during their hospitalization course according to
a pre-specified treatment scheme and constituted the treat-
ment arm in this study. The results in this treatment arm
were compared with those of a population of 100 consecu-
tive dyspnoeic ED patients enrolled previously between July
2014 and May 2015 using the exact same inclusion criteria,
constituting the standard care arm in this study. Inclusion
criteria consisted of dyspnoea at rest, structural heart dis-
ease on conventional echo, a baseline brain natriuretic pep-
tide (BNP) > 100 ng/L, medial E/e0 > 15, and pulmonary
congestion, that is, either bilateral B-lines or bilateral pleu-
ral fluid, on LUS. Exclusion criteria consisted of altered men-
tal status, chronic dialysis, mitral stenosis, pulmonary
fibrosis, or a prosthetic valve in the mitral position. Struc-
tural heart disease on echo was defined as depressed sys-
tolic function, as significant (severe) valve disease, or as
key structural or functional alterations indicating cardiac
dysfunction. The latter structural or functional alterations
mainly were related to ventricular hypertrophy, enlarged
atria, or impaired diastolic tissue Doppler velocities, as is
outlined for HF with preserved ejection fraction (EF) in the
current guidelines.6,7
Treatment was altered according to a pre-specified treat-
ment protocol, aiming at decreasing cardiac filling pressures
and resolving pulmonary congestion. The primary endpoints
for estimating treatment efficacy consisted of decrease in
congestive parameters, that is, BNP, symptoms, pulmonary
congestion, cardiac filling pressures, and cumulative fluid
loss, as well as length of stay during hospitalization. The
secondary endpoints consisted of adverse events, that is,
symptomatic hypotension or acute kidney injury (AKI), as well
as 6 month survival regarding the combined endpoint of re-
hospitalization for AHF or all-cause mortality.
All enrolled patients had the CaTUS protocol, alongside
laboratory and clinical parameters obtained at baseline in
the ED, and thereafter daily between 8 and 10 a.m. during
hospitalization, including the day of discharge. Patients in
the treatment arm had their treatment guided on a daily ba-
sis according to the CaTUS protocol, whereas patients in the
standard care arm had CaTUS performed daily solely for
follow-up. Treating physicians of the standard care arm-
patients would have access to the results of the CaTUS proto-
col for ethical reasons, if they so wished. Additionally, a con-
ventional echo exam was performed to all patients at
baseline in the ED, in which precise methodology is described
in Appendix A. Laboratory samples consisted of daily blood
count, creatinine, electrolytes, and BNP. All ultrasound
exams were performed with the Philips (Royal Philips,
Amsterdam, Netherlands) CX 50® device using the cardiac
(S5-1) probe only. A written consent was obtained from all
participating patients, and the study was approved by the lo-
cally appointed ethics committee. This study complies with
the Declaration of Helsinki.
Cardiothoracic ultrasound protocol
The components of the CaTUS protocol are shown in Figure 1
and included a focused echo and LUS. All CaTUS measure-
ments were performed with the patient in a supine position,
with the upper body elevated at an angle of approximately
30°. The focused echo exam in the CaTUS protocol evaluating
cardiac filling pressures included medial E/e0 ratio and a five-
class, scaled inferior vena cava (IVC) index, derived from IVC cal-
ibre and respiratory variation (RV). IVC index was scaled from 1
to 5, with grade 1 representing a narrow, entirely collapsing IVC;
grade 2 a maximum diameter (MD) < 21 mm and RV > 50%;
grade 3 anMD≥ 21mmor anRV< 50%, grade 4 anMD≥ 21mm
and an RV < 50%; and grade 5 an MD ≥ 21 mm with negligible
RV and dilated hepatic veins. IVC measurements were per-
formed using M-mode whenever feasible, 1–2 cm caudally of
the first hepatic vein.
Focused echocardiography and LUS protocol 121
ESC Heart Failure 2018; 5: 120–128
DOI: 10.1002/ehf2.12208
Lung ultrasound was performed using a rapid six-zone scan
protocol designed for daily monitoring and included evalua-
tion of B-lines in two regions bilaterally: the apical and mam-
millary regions using vertical orientation in a mid/lateral
clavicular line. Additionally, pleural fluid was searched in the
lower basal regions bilaterally. LUS was classified as conges-
tive if there were three or more B-lines in at least one region
bilaterally, or >5 mm of free pleural fluid bilaterally. Decon-
gestion on LUS was defined as resolution of both bilateral
B-lines and pleural fluid. Patients who were decongested on
LUS on the day of discharge were defined as LUS responders,
whereas patients discharged with residual pulmonary con-
gestion were defined as non-responders.
The E-wave was recorded using pulsed wave Doppler at
the tips of the opened mitral valve. If the patient was in sinus
rhythm, or any other regular rhythm, three consecutive
cycles at end expiration were recorded, and the average of
these three E-waves was registered. If the patient was
presenting with an irregular rhythm, such as atrial fibrillation
or extra-systolia, five consecutive cycles and the average
of these five E-waves were registered. Sweep speed was
adjusted to fit a proper number of cardiac cycles into one
picture frame. The e0 wave was measured using tissue pulsed
wave Doppler with the sample volume placed at the medial
mitral annulus. The E/e0 was obtained in the four-chamber
window using minimal angulation. Gain settings were opti-
mized to obtain a crisp, clear signal without signal aberration.
All CaTUS examinations were performed by a single sonog-
rapher with over 5 years of experience in both LUS and echo
in daily practice. As this was a single-centre, single-operator
study, LUS classification, as well as echocardiographic filling
pressure measurements (E/e0 and IVC grading), was validated
on a separate subset of 20 patients with experienced blinded
validators (one validator for LUS and another for filling
pressures), being reported in the results section.
Cardiothoracic ultrasound-guided treatment in the
treatment arm
According to the pre-specified treatment protocol, the
primary treatment targets within the treatment arm in
priority order were (1) resolution of pulmonary congestion
on LUS as defined earlier (resolution of both bilateral B-lines
and pleural fluid), (2) an E/e0 of <15, and (3) an IVC
grade ≤ 2.
Decongestive pharmacologic therapy consisted mainly of
loop diuretics and vasodilators. In case of diuretic resistance,
early combination with thiazide diuretics or mineralocorticoid
receptor antagonists at diuretic doses, and if necessary also
ultrafiltration, was considered. Mineralocorticoid receptor
antagonists were considered earlier in cases of hypokalaemia.
Other pharmacologic or procedural evidence-based HF
therapies, such as devices, beta-blockers, and angiotensin-
Figure 1 Cardiothoracic ultrasound protocol showing B-lines on lung ultrasound as a sign of congestion, pleural fluid, a typical mitral inflow, and tissue
Doppler signals used to calculate the E/e0 ratio, as well as a subcostal view of the IVC. E/e0, E/e0 ratio medially; IVC, inferior vena cava.
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converting enzyme inhibitors, were administered per usual
protocol during hospitalization.
Pre-specified adverse events, causing discontinuation of
decongestive therapy, consisted of hypotension or signs of
hypoperfusion in combination with symptoms or AKI. In case
of such adverse events, decongestive treatment was halted
before treatment targets 2 or 3 were achieved, as long as
the primary treatment target, that is, resolution of pulmonary
congestion, was achieved. AKI was defined as a rise in creat-
inine of >26.5 μmol/mL or a rise in creatinine >1.5 times
within 48 h as originally defined by the Acute Kidney Injury
Network criteria. Hypotension was defined as a systolic arte-
rial blood pressure of <100 mmHg or a mean arterial blood
pressure < 65 mmHg, while hypoperfusion was defined as
two or more cold extremities from the wrist or ankle distally.
Statistical analysis
SPSS version 23 was used for statistical analysis. Continuous
variables were presented as mean values including standard
deviation or median values including interquartile range as
was appropriate. Categorical variables were presented as
counts and percentages. Differences between two groups
were determined by unpaired t-test or Mann–Whitney U-test
for continuous variables and Pearson chi-square for grouping
variables. Differences in survival between groups were
analysed with the log-rank test and graphically displayed with
Kaplan–Meier survival curve. Univariate analysis by Cox
proportional hazards model was performed to assess the
association between each group.
Results
Baseline characteristics of patients in the treatment arm as
compared with those of the follow-up arm can be seen in
Table 1. Forty-five percent of the patients had an EF < 40%,
23% had an EF between 40% and 50%, and 32% had an
EF > 50%. There were no significant differences in any of
these baseline parameters on admission between the groups
Table 1 Baseline characteristics in the treatment arm compared with those in the standard care arm
All Treatment arm Standard care arm P
Baseline characteristics
Age (years) 76.0 (SD 10.6) 75.3 (SD 9.65) 76.2 (SD 10.8) 0.736
Male gender 50.0% 50.0% 50.0% 1.000
Diabetes 45.0% 50.0% 44.0% 0.622
Hypertension 85.8% 85.0% 90.0% 0.434
Coronary artery disease 45.8% 35.0% 48.0% 0.287
Previous HF 60.8% 55.0% 62.0% 0.558
Pulmonary disease 2.5% 5.0% 2.0% 0.433
Clinical parameters
Systolic BP (mmHg) 145 (SD 30.7) 144 (SD 18.6) 145 (SD 32.5) 0.892
Pulse rate (/min) 84.5 (SD 22.6) 86.2 (SD 26.8) 84.1 (SD 21.9) 0.723
Sinus rhythm 47.5% 35.0% 50.0% 0.220
Bundle branch block 38.3% 30.0% 40.0% 0.383
Dyspnoea VAS score (0–10) 6.15 (SD 2.53) 5.89 (SD 2.02) 6.20 (SD 2.62) 0.633
Rales on auscultation 30.0% 30.0% 30.0% 1.000
Obstruction on auscultation 20.0% 10.0% 18.0% 0.381
Respiratory rate (/min) 22.6 (SD 5.67) 20.7 (SD 3.61) 23.0 (SD 5.93) 0.111
Respiratory support 39.2% 35.0% 40.0% 0.796
Echo parameters
Left ventricular EF (%) 42.34 42.6 (SD 14.2) 42.3 (SD 16.5) 0.945
E/e0 20.67 20.8 (SD 4.05) 20.6 (SD 4.21) 0.859
e0 5.79 6.29 (SD 1.25) 5.69 (SD 1.58) 0.113
Significant valve disease 56.7% 55.0% 57.0% 0.869
Estimated SPaP (mmHg) 66.7 (SD 18.7) 64.1 (SD 17.9) 67.4 (SD 18.9) 0.558
IVCi 3.28 (SD 0.65) 3.74 (SD 0.57) 3.20 (SD 0.63) <0.001
RV dysfunction 30.0% 45.0% 27.0% 0.109
Laboratory
BNP (ng/L) 696 (342–1497) 543 (296–900) 715 (365–1676) 0.072
eGFR (mL/min/1.73 m2) 57.2 (SD 25.3) 61.7 (SD 24.2) 56.3 (SD 25.5) 0.391
Haemoglobin 120 (SD 20.7) 119 (SD 20.1) 120 (SD 20.9) 0.822
BNP, brain natriuretic peptide; BP, blood pressure; E/e0, medial E to e0 ratio; EF, ejection fraction; eGFR, estimated glomerular filtration
rate; HF, heart failure; IVCi, inferior vena cava index (scale 1–5); RV, right ventricle; SD, standard deviation; SPaP, systolic pulmonary artery
pressure; VAS, visual analogue scale. Bold means statistically significant.
Values are expressed as mean ± SD except for BNP expressed as median (25th–75th interquartile percentile). Categorical variables are
expressed as number of cases (%).
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except for IVC index, which was higher in the treatment arm,
indicating higher right-sided filling pressures in this group.
Within the whole 120 patient study population, LUS
responders, that is, patients achieving the primary treatment
target of pulmonary decongestion on LUS as evaluated on the
day of discharge, experienced a significantly better post-
discharge prognosis regarding both 6 month all-cause mortal-
ity, as well as the composite endpoint of 6 month all-cause
mortality or hospitalization for AHF (Figure 2) compared with
non-responders, that is, patients discharged with residual
pulmonary congestion on LUS. In comparing these two
groups at baseline, LUS responders had a lower baseline
BNP with no other significant differences in on-admission
parameters between LUS responders and non-responders
(Table 2).
As can be seen in Table 3, patients in the treatment arm
had a significantly greater improvement in all decongestive
parameters during treatment, including echocardiographic
parameters, pulmonary congestion on LUS, natriuretic
peptides, fluid loss, and symptoms compared with those in
the standard care arm. Patients in the treatment arm also
experienced non-significantly less adverse events, with no ad-
verse events associated with hypotension or hypoperfusion,
and displayed a significantly shorter mean hospitalization,
lasting less than 4 days on average (Table 3).
Patients in the treatment arm also presented a signifi-
cantly lower 6 month event rate regarding the combined
endpoint of all-cause mortality and re-hospitalization due to
AHF (Figure 3, log rank P = 0.017). This difference was mainly
driven by a significantly larger difference in re-hospitalization
(log rank P = 0.005), while there was only a non-significant
trend towards a lower all-cause mortality (log rank P = 0.488).
The CaTUS exam was rapid to perform, lasting <5 min in
all patients during the first 30 time-measured exams. Regard-
ing qualitative validations of LUS and focused echo, inter-
observer agreement for congestion on LUS was 100%, and
Figure 2 Six-month survival regarding (A) all-cause mortality and (B) the composite endpoint of all-cause mortality or hospitalization for AHF in LUS
responders, that is, patients who experienced resolution of pulmonary congestion on lung ultrasound, compared with that in non-responders. AHF,
acute heart failure; LUS, lung ultrasound.
124 Ö. Jonas et al.
ESC Heart Failure 2018; 5: 120–128
DOI: 10.1002/ehf2.12208
Table 3 Treatment-related parameters in the treatment arm compared with those in the standard care arm
Treatment arm Standard care arm
Pn = 20 n = 100
During hospitalization
Decrease in E/e0 6.48 (SD 2.92) 2.62 (SD 4.67) 0.001
Decrease in IVCi (1–5) 1.79 (SD 1.02) 0.39 (SD 0.82) <0.001
% decrease in BNP (ng/L) 35.9 (SD 26.3) 16.6 (SD 61.1) 0.029
LOH (days) 3.74 (SD 2.02) 6.85 (SD 4.22) 0.002
Cumulative fluid loss (mL) 5447 (SD 5364) 3072 (SD 3059) <0.001
Decrease in eGFR (mL/min/1.73 m2) 3.47 (SD 8.64) 4.41 (SD 13.8) 0.778
On the day of discharge
Final E/e0 14.4 (SD 3.14) 18.0 (SD 5.63) 0.007
Final IVCi (1–5) 1.21 (SD 0.91) 1.82 (SD 0.76) 0.005
Final BNP (ng/L) 249 (172–408) 426 (242–1015) 0.011
Pulmonary decongested on LUS 80.0% 53.0% 0.039
E/e0 <15 60.0% 35.0% 0.020
Pulmonary decongestion or E/e0 < 15 95.0% 63.0% 0.007
Asymptomatic at discharge 95.0% 72.0% 0.036
Final eGFR (mL/min/1.73 m2) 58.3 (SD 24.2) 51.9 (SD 23.8) 0.287
Adverse events
Acute kidney injury 15.0% 21.0% 0.617
Symptomatic hypotension 0% 4.0% 0.378
BNP, brain natriuretic peptide; E/e0, medial E to e0 ratio; eGFR, estimated glomerular filtration rate; IVCi, inferior vena cava index (scale 1–5);
LOH, length of hospitalization; LUS, lung ultrasound; SD, standard deviation. Bold means statistically significant.
Values are expressed as mean ± SD except for BNP expressed as median (25th–75th interquartile percentile). Categorical variables are
expressed as number of cases (%).
Table 2 Baseline characteristics in the lung ultrasound responders, that is, patients who achieved pulmonary decongestion, compared
with those in non-responders
All LUS responders (n = 69) Non-responders (n = 51) P
Baseline characteristics
Age (years) 76.0 (SD 10.6) 75.0 (SD 11.5) 77.4 (SD 9.07) 0.228
Male gender 50.0% 49.3% 51.0% 1.000
Diabetes 45.0% 47.8% 41.2% 0.571
Hypertension 83.3% 79.7% 88.2% 0.322
Coronary artery disease 45.8% 44.9% 47.1% 0.854
Previous HF 60.8% 53.6% 70.6% 0.088
Pulmonary disease 2.5% 2.9% 2.0% 1.000
Clinical parameters
Systolic BP (mmHg) 145 (SD 30.7) 148 (SD 29.8) 140 (SD 31.3) 0.138
Pulse rate (/min) 84.5 (SD 22.6) 84.7 (SD 23.5) 84.1 (SD 21.7) 0.881
Sinus rhythm 47.5% 42.0% 54.9% 0.197
Bundle branch block 38.3% 42.0% 33.3% 0.345
Dyspnoea VAS score (0–10) 6.15 (SD 2.53) 6.18 (SD 2.53) 6.10 (SD 2.55) 0.847
Rales on auscultation 30.0% 33.3% 25.5% 0.422
Obstruction on auscultation 16.7% 18.8% 13.7% 0.621
Respiratory rate (/min) 22.6 (SD 5.67) 22.6 (SD 5.48) 22.6 (SD 5.98) 0.985
Respiratory support 39.2% 42.0% 36.0% 0.571
Echo parameters
Left ventricular EF (%) 42.3 (SD 16.1) 42.9 (SD 16.2) 41.5 (SD 16.1) 0.628
E/e0 20.7 (SD 4.17) 20.5 (SD 3.89) 20.9 (SD 4.56) 0.573
e0 5.79 (SD 1.55) 5.90 (SD 1.45) 5.63 (SD 1.68) 0.339
Significant valve disease 56.7% 55.1% 58.8% 0.713
Estimated SPaP (mmHg) 66.7 (SD 18.7) 63.5 (SD 17.9) 71.4 (SD 18.9) 0.077
IVCi 3.28 (SD 0.65) 3.32 (SD 0.65) 3.22 (SD 0.64) 0.391
RV dysfunction 30.0% 30.4% 29.4% 1.000
Laboratory
BNP (ng/L) 696 (342–1497) 602 (328–962) 942 (373–1782) 0.027
eGFR (mL/min/1.73 m2) 57.2 (SD 25.3) 59.3 (SD 24.6) 54.2 (SD 26.1) 0.279
Haemoglobin 120 (SD 20.7) 119 (SD 20.1) 120 (SD 20.9) 0.822
BNP, brain natriuretic peptide; BP, blood pressure; E/e0, medial E to e0 ratio; EF, ejection fraction; eGFR, estimated glomerular filtration
rate; HF, heart failure; IVCi, inferior vena cava index (scale 1–5); LUS, lung ultrasound; RV, right ventricle; SD, standard deviation; SPaP,
systolic pulmonary artery pressure; VAS, visual analogue scale. Bold means statistically significant.
Values are expressed as mean ± SD except for BNP expressed as median (25th–75th interquartile percentile). Categorical variables are
expressed as number of cases (%).
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thus the κ coefficient was 1.0. For IVC index, the mean inter-
observer coefficient of variation was 4.37%, and for E/e0 9.99%.
Discussion
This study was designed to test the CaTUS protocol for
guiding decongestive AHF treatment in a small pilot sample,
constituting the treatment arm. The results within this
population were compared with those of a larger population,
enrolled earlier for follow-up purposes, who were treated per
standard, daily-basis protocol during their hospitalization by
their treating physicians. Treatment in this standard care
arm was considered to reflect standard in-hospital treatment
for AHF in a tertiary care hospital, with the exception that, for
ethical reasons, treating physicians would have access to
results of the CaTUS exams if they so wished.
As such, the groups were not balanced, and the treatment
arm was considered too small for prognostic purposes.
Nevertheless, patients in the treatment arm experienced
substantially greater decongestion as estimated by every
congestive parameter during a significantly shorter mean
hospitalization, and perhaps most importantly, no safety
issues associated with CaTUS-guided treatment occurred.
Patients in the treatment arm further showed a signal
towards improved prognosis, mainly driven by a reduction
in re-hospitalizations.
In the standard care arm, almost half of the patients were
discharged with residual pulmonary congestion and over one-
fourth with dyspnoea at rest. These rather poor results are in
line with those of previous studies, underlining current
difficulty of achieving adequate decongestion during AHF
hospitalizations, even though residual congestion is known
to have a detrimental impact on prognosis,4,15–17 as was the
case in this study as well.
Factors explaining the difficulty of achieving adequate de-
congestion during in-hospital AHF treatment are poorly un-
derstood but may include excessive intravenous fluid and
sodium load during lengthier hospitalizations18 and diuretic
resistance or inadequate diuretic dosing,19 resulting in failure
to achieve a negative sodium and fluid balance. Some patients
also seem to suffer from vasoconstriction and fluid misdistribu-
tion rather than pure volume overload, probably requiring an
individualized, more vasodilative treatment approach.8,9,20 De-
congestive therapy may also be halted owing to assumed ad-
verse events, mainly kidney injury, which may theoretically
occur as a result of excess diuretic therapy.21 In association
with AHF, however, AKI may also occur owing to increased sys-
temic venous congestion and hypervolaemia,22 in which case
fluid removal might conversely improve kidney function.23 Per-
haps most importantly, AKI in combination with adequate de-
congestion does not seem to impair prognosis, thus
representing a sort of ‘benign’ AKI partly owing to haemo-
concentration, whereas the very opposite is true in case of
AKI in combination with persistent congestion.23,24 This under-
lines the importance of haemodynamic monitoring when
treating AHF, especially in the case of renal failure.
In chronic HF, guidance of decongestive therapy by pulmo-
nary artery pressure was associated with a significant reduc-
tion in hospitalizations in the outpatient CHAMPION trial,25
but in AHF, no such positive trials on treatment guidance
exist. In the ESCAPE trial, AHF treatment guided by pulmonary
artery catheter was non-useful compared with conventional
therapy.26 It is noteworthy, however, that physicians treating
ESCAPE trial patients had central venous pressure measure-
ments and echocardiograms available on a daily basis in both
groups, although their role for guiding treatment was not
clearly reported. The study setting in this study was quite
close to that seen in the ESCAPE trial, but the benefits of echo
compared with those of pulmonary artery catheter include
the lack of adverse events and feasibility also outside an inten-
sive care unit setting.
Cardiac filling pressures, considered the driving force
behind pulmonary congestion, have shown potential to
decrease rapidly following aggressive AHF treatment
initiation,27,28 while pulmonary decongestion can be assessed
Figure 3 Six-month survival regarding the composite endpoint of all-cause death or hospitalization for AHF in the treatment arm, receiving cardiotho-
racic ultrasound-guided therapy, as compared with that in the standard care arm. AHF, acute heart failure.
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in real time with LUS.14 Echo-derived filling pressures and LUS
have also displayed prognostic significance prior to discharge,
making them potential treatment targets during AHF hospital-
izations.16,17,29 As patients discharged with pulmonary conges-
tion are known to carry a poor prognosis,16,17 resolution of
pulmonary congestion constituted our primary treatment tar-
get in our treatment protocol. In our own previous study
analysing chronologic improvement in E/e0, IVC index, and pul-
monary congestion on LUS, we found E/e0 to precede pulmo-
nary decongestion among treatment-responsive patients,
which took place with a mean E/e0 value of 17.2.30 E/e0 there-
after continued declining towards the end of hospitalization,
reaching a mean discharge value of 16.2, still considered abnor-
mal, while IVC index declined later towards end of hospitaliza-
tion. Thus, the two latter treatment targets, that is, close-to-
normal left-sided cardiac filling pressures and a non-plethoric
IVC, represent attempts to achieve more thorough deconges-
tion prior to discharge, after resolution of pulmonary deconges-
tion. Although our pre-specified treatment protocol included an
order to halt therapy in case of adverse events associated with
over-aggressive treatment, this did not become an issue in this
study, as no such events occurred in the treatment arm.
Eventually, patients in the treatment arm seemed to be
more thoroughly decongested by every parameter after
receiving CaTUS-guided therapy as compared with patients
who received standard care. Post-discharge prognosis in the
treatment arm was also significantly better despite a low
number of patients in this arm, lowering the statistical power
of the survival analysis. Concurrently, though, this small
population size simultaneously requires these intriguing
results to be interpreted with caution. Nevertheless, CaTUS-
guided therapy with our treating protocol was feasible and
seemed safe, and no larger practical issues occurred while
using it. Future randomized trials with bigger balanced popu-
lations are needed in order to define whether individualized
ultrasound-guided treatment could improve prognosis and
shorten hospitalizations.
Study limitations
This was a small pilot study with unequal populations, with
the two non-randomized populations enrolled during
sequential time periods. Nevertheless, these two populations
were not convenience samples but sequential patients enter-
ing the ED, thus diminishing the chance of selection bias. This
study was a single-operator, single-centre study, although
the CaTUS measurements were blindly validated with high
agreement. Exact cumulative doses of medications used
could also not be archived, and hence we could not report
prognostically important dose-related measures such as
cumulative use of diuretics and diuretic resistance.
Conclusions
In this small pilot trial, CaTUS seemed safe and feasible for
guiding AHF treatment. Ultrasound-guided AHF treatment
might be associated with improved total decongestion,
shorter hospitalizations, and improved prognosis, which need
to be verified in future trials.
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Appendix A: Conventional echo
All patients enrolled in the study had a comprehensive
echocardiography performed by experienced operators in
order to evaluate for structural heart disease. Left ventricular
ejection fraction was measured using Simpsons bi-plane
method of discs. Right ventricle dysfunction was defined as
either tricuspid annular plane systolic excursion < 16 mm
or a fractional area change < 35%. The presence of signifi-
cant valve disease was reported as evaluated by the echocar-
diographer. E-waves, A-waves, and tissue Doppler imaging
velocities were recorded as described earlier concerning the
cardiothoracic ultrasound protocol. Mitral stenosis as an
exclusion criterion was defined as a mitral inflow pressure
half-time > 70 ms or a mitral inflow mean gradient of
>5 mmHg. The presence of structural heart disease was
defined as described in the guidelines.
References
1. van Riet EE, Hoes AW, Wagenaar KP,
Limburg A, Landman MA, Rutten FH.
Epidemiology of heart failure: the preva-
lence of heart failure and ventricular
dysfunction in older adults over time. A
systematic review. Eur J Heart Fail 2016
Mar; 18: 242–252.
2. Adams KF Jr, Fonarow GC, Emerman CL,
LeJemtel TH, Costanzo MR, Abraham
WT, Berkowitz RL, Galvao M, Horton
DP; ADHERE Scientific Advisory Commit-
tee and Investigators. Characteristics and
outcomes of patients hospitalized for
heart failure in the United States:
rationale, design, and preliminary obser-
vations from the first 100,000 cases in
the Acute Decompensated Heart Failure
National Registry (ADHERE). Am Heart
J 2005; 149: 209–216.
3. Ambrosy AP, Fonarow GC, Butler J,
Chioncel O, Greene SJ, Vaduganathan
Focused echocardiography and LUS protocol 127
ESC Heart Failure 2018; 5: 120–128
DOI: 10.1002/ehf2.12208
M, Nodari S, Lam CS, Sato N, Shah AN,
Gheorghiade M. The global health and
economic burden of hospitalizations for
heart failure: lessons learned from hos-
pitalized heart failure registries. J Am
Coll Cardiol 2014; 63: 1123–1133.
4. Greene SJ, Fonarow GC, Vaduganathan
M, Khan SS, Butler J, Gheorghiade M.
The vulnerable phase after hospitaliza-
tion for heart failure. Nat Rev Cardiol
2015; 12: 220–229.
5. Ambrosy AP, Cerbin LP, Armstrong PW,
Butler J, Coles A, DeVore AD, Dunlap
ME, Ezekowitz JA, Felker GM, Fudim
M, Greene SJ, Hernandez AF, O’Connor
CM, Schulte P, Starling RC, Teerlink JR,
Voors AA, Mentz RJ. Body weight
change during and after hospitalization
for acute heart failure: patient character-
istics, markers of congestion, and out-
comes: findings from the ASCEND-HF
Trial. JACC Heart Fail 2017; 5: 1–13.
6. Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC,
Geraci SA, Horwich T, Januzzi JL, Johnson
MR, Kasper EK, Levy WC, Masoudi FA,
McBride PE, McMurray JJ, Mitchell JE, Pe-
terson PN, Riegel B, Sam F, Stevenson LW,
Tang WH, Tsai EJ, Wilkoff BL; American
College of Cardiology Foundation; Ameri-
can Heart Association Task Force on Prac-
tice Guidelines. 2013 ACCF/AHA
guideline for the management of heart
failure. Circulation 2013; 128: 240–327.
7. Ponikowski P, Voors AA, Anker SD, Bueno
H, Cleland JG, Coats AJ, Falk V, González-
Juanatey JR, Harjola VP, Jankowska EA,
Jessup M, Linde C, Nihoyannopoulos P,
Parissis JT, Pieske B, Riley JP, Rosano
GM, Ruilope LM, Ruschitzka F, Rutten
FH, van der Meer P; Authors/Task Force
Members. 2016 ESC guidelines for the di-
agnosis and treatment of acute and
chronic heart failure: the task force for
the diagnosis and treatment of acute
and chronic heart failure of the European
Society of Cardiology (ESC). Developed
with the special contribution of the Heart
Failure Association (HFA) of the ESC. Eur
Heart J 2016; 37: 2129–2200.
8. Weintraub NL, Collins SP, Pang PS, Levy
PD, Anderson AS, Arslanian-Engoren C,
Gibler WB, McCord JK, Parshall MB,
Francis GS, Gheorghiade M; American
Heart Association Council on Clinical Car-
diology and Council on Cardiopulmonary,
Critical Care, Perioperative and Resuscita-
tion. Acute heart failure syndromes: emer-
gency department presentation,
treatment, and disposition: current ap-
proaches and future aims. A scientific
statement from the American Heart Asso-
ciation. Circulation 2010; 122: 1975–1996.
9. Martens P, Nijst P, Mullens W. Current
approach to decongestive therapy in
acute heart failure. Curr Heart Fail Rep
2015 Dec; 12: 367–378.
10. Gheorghiade M1, Follath F, Ponikowski
P, Barsuk JH, Blair JE, Cleland JG,
Dickstein K, Drazner MH, Fonarow GC,
Jaarsma T, Jondeau G, Sendon JL,
Mebazaa A, Metra M, Nieminen M, Pang
PS, Seferovic P, Stevenson LW, van
Veldhuisen DJ, Zannad F, Anker SD,
Rhodes A, McMurray JJ, Filippatos G;
European Society of Cardiology;
European Society of Intensive Care Med-
icine. Assessing and grading congestion
in acute heart failure: a scientific state-
ment from the acute heart failure com-
mittee of the Heart Failure Association
of the European Society of Cardiology
and endorsed by the European Society
of Intensive Care Medicine. Eur J Heart
Fail 2010 May; 12: 423–433.
11. Ang SH. Lung ultrasound in the manage-
ment of acute decompensated heart fail-
ure. Curr Cardiol Rev 2012; 8: 123–136.
12. Beigel R, Cercek B, Arsanjani R, Siegel
RJ. Echocardiography in the use of non-
invasive hemodynamic monitoring. J
Crit Care 2014; 29: 184–188.
13. Papadimitriou L, Georgiopoulou VV, Kort
S, Butler J, Kalogeropoulos AP. Echocardi-
ography in acute heart failure: current per-
spectives. J Card Fail 2016 Jan; 22: 82–94.
14. Strnad M, Prosen G, Borovnik Lesjak V.
Bedside lung ultrasound for monitoring
the effectiveness of prehospital treat-
ment with continuous positive airway
pressure in acute decompensated heart
failure. Eur J Emerg Med 2016; 1: 50–55.
15. Lala A, Mcnulty SE, Mentz RJ, Dunlay
SM, Vader JM, AbouEzzeddine OF,
DeVore AD, Khazanie P, Redfield MM,
Goldsmith SR, Bart BA, Anstrom KJ,
Felker GM, Hernandez AF, Stevenson
LW. Relief and recurrence of congestion
during and after hospitalization for acute
heart failure: insights from Diuretic Opti-
mization Strategy Evaluation in Acute De-
compensated Heart Failure (DOSE-AHF)
and Cardiorenal Rescue Study in Acute
Decompensated Heart Failure (CARESS-
HF). Circ Heart Fail 2015; 4: 741–748.
16. Coiro S, Rossignol P, Ambrosio G,
Carluccio E, Alunni G, Murrone A, Tritto
I, Zannad F, Girerd N. Prognostic value
of residual pulmonary congestion at dis-
charge assessed by lung ultrasound im-
aging in heart failure. Eur J Heart Fail
2015; 11: 1172–1181.
17. Gargani L, Pang PS, Frassi F, Miglioranza
MH, Dini FL, Landi P, Picano E. Persistent
pulmonary congestion before discharge
predicts rehospitalization in heart failure:
a lung ultrasound study. Cardiovasc Ultra-
sound 2015; 4: 13–40.
18. Tafreshi J, Hoang TM, Grigorian T, Pai
AD, Tafreshi AR, Pai RG. Impact of iatro-
genic, excessive, nondietary sodium ad-
ministration in patients with acute
heart failure exacerbation on hospital
length of stay. Pharmacotherapy 2011
Jan; 31: 58–61.
19. Bonow RO, Mann DL, ZIpes DP, Libby P.
Braunwald’s Heart Disease: A Textbook of
Cardiovascular Medicine. Vol 10. ch 28,
p. 557
20. Colombo PC, Doran AC, Onat D, Wong
KY, Ahmad M, Sabbah HN, Demmer
RT. Venous congestion, endothelial and
neurohormonal activation in acute
decompensated heart failure: cause or
effect? Curr Heart Fail Rep 2015; 12:
215–222.
21. Wu X, Zhang W, Ren H, Chen X, Xie J,
Chen N. Diuretics associated acute kid-
ney injury: clinical and pathological
analysis. Ren Fail 2014; 36: 1051–1055.
22. Mullens W, Abrahams Z, Francis GS,
Sokos G, Taylor DO, Starling RC, Young
JB, Tang WH. Importance of venous con-
gestion for worsening of renal function in
advanced decompensated heart failure. J
Am Coll Cardiol 2009; 53: 589–596.
23. Damman K, Testani JM. The kidney in
heart failure: an update. Eur Heart J
2015; 36: 1437–1444.
24. Testani JM, Chen J, McCauley BD,
Kimmel SE, Shannon RP. Potential ef-
fects of aggressive decongestion dur-
ing the treatment of decompensated
heart failure on renal function and sur-
vival. Circulation 2010; 122: 265–272.
25. Abraham WT, Stevenson LW, Bourge RC,
Lindenfeld JA, Bauman JG, Adamson PB;
CHAMPION Trial Study Group. Sustained
efficacy of pulmonary artery pressure to
guide adjustment of chronic heart failure
therapy: complete follow-up results from
the CHAMPION randomised trial. Lancet
2016; 387: 453–461.
26. Binanay C, Califf RM, Hasselblad V,
O’Connor CM, Shah MR, Sopko G, Ste-
venson LW, Francis GS, Leier CV, Miller
LW; ESCAPE Investigators and ESCAPE
Study Coordinators. Evaluation study
of congestive heart failure and pulmo-
nary artery catheterization effective-
ness: the ESCAPE trial. JAMA 2005;
294: 1625–1633.
27. Harada K, Yamamoto T, Okumura T,
Shigekiyo M, Terada N, Okada A, Kawata
A, Iima T, Harada T, Fujisawa K,
Kageyama N, Saito A, Yamamoto H,
Fujinaga H. Intravenous nicorandil for
treatment of the urgent phase acute heart
failure syndromes: a randomized, con-
trolled trial. Eur Heart J Acute Cardiovasc
Care 2016; 16 (Epub ahead of print).
28. Ponikowski P, Mitrovic V, Ruda M,
Fernandez A, Voors AA, Vishnevsky A,
Cotter G, Milo O, Laessing U, Zhang Y,
Dahlke M, Zymlinski R, Metra M. A ran-
domized, double-blind, placebo-
controlled, multicentre study to assess
haemodynamic effects of serelaxin in
patients with acute heart failure. Eur
Heart J 2014; 35: 431–441.
29. Gackowski A, Isnard R, Golmard JL,
Pousset F, Carayon A, Montalescot G,
Hulot JS, Thomas D, Piwowarska W,
Komajda M. Comparison of echocardi-
ography and plasma B-type natriuretic
peptide for monitoring the response to
treatment in acute heart failure. Eur
Heart J 2004; 25: 1788–1796.
30. Öhman J, Harjola VP, Karjalainen P,
Lassus J. Assessment of early treatment
response by rapid cardiothoracic
ultrasound in acute heart failure: car-
diac filling pressures, pulmonary
congestion and mortality. Eur Heart J
Acute Cardiovasc Care. https://doi.org/
10.1177/2048872617708974
128 Ö. Jonas et al.
ESC Heart Failure 2018; 5: 120–128
DOI: 10.1002/ehf2.12208
